EN / CN

News

Current Position: Home ››  News

23

2026Year07Month

Amlodipine Besylate API Approved for Marketing!

Newland Pharmaceutical's Amlodipine Besylate API has received NMPA marketing approval, marking another step forward in the company's cardiovascular API portfolio.
[View Details]

19

2026Year07Month

Set Benchmarks · Embark Anew | Newland Pharma Amoeba Management Phase I Commendation & Training Conference Concludes Successfully

On July 18, Xintiandi Pharma held the Phase I commendation and training activity for the Amoeba Management Project in the multi-functional lecture hall on the third floor of the company. The event was attended by the company’s middle and senior management personnel, all Amoeba leaders, and senior consultants from Bomington Consulting. Centering on phased work summary, outstanding employee recognit
[View Details]

06

2026Year07Month

Meet Newland in Bangkok | CPHI Southeast Asia 2026

Join us at Booth L49 to explore new opportunities in the ASEAN pharmaceutical market and discuss potential partnerships.
[View Details]

23

2026Year06Month

Levamlodipine Besylate API Approved for Marketing!

Newland Pharmaceutical's Levamlodipine Besylate API is now approved for marketing by the NMPA.
[View Details]

21

2026Year06Month

Newland at CPHI China 2026 | APIs, Intermediates & CDMO Solutions

Newland Pharmaceutical connects with global industry partners at CPHI China 2026, highlighting its APIs, intermediates, and CDMO capabilities.
[View Details]
Total53Items   1 / 11Page  Per Page5Items  First Page  Previous  Next  Last Page